Anthrax Antitoxin (monoclonal antibody)
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 75A50324C00006
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50324C00006 Federal contract award
- Awardee
- Elusys Therapeutics Inc.
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
This Limited/Sole Source Justification Notice is for the procurement of an FDA-approved anthrax antitoxin (monoclonal antibody) by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The Notice justifies the use of a limited/sole source procurement approach under Solicitation Number 75A50324C00006, which resulted in a contract award to an unknown vendor on 2024-04-30 for an unknown amount. The rationale for the limited/sole source approach is not explicitly stated in the summarized details provided.
Notice text
Justification and Approval relating to procurement of FDA-approved anthrax antitoxin (monoclonal antibody) is hereby published in accordance with FAR 6.305(a).
Awarded contract 75A50324C00006 to unknown vendor for unknown amount on 2024-04-30.
Files
| File | Type | Posted |
|---|---|---|
| JA_Anthim_Redacted.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity